Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PROCEPT BioRobotics Corp (PRCT)

PROCEPT BioRobotics Q3 revenue rises 18% to $98.3 million; net loss widens

Mixed Impact 3 of 5 earnings Written later

PROCEPT BioRobotics reported third-quarter 2026 revenue of $98.3 million, up 18% from a year earlier, with U.S. procedures up about 22%. The net loss widened to $26.5 million from $21.4 million as operating expenses rose to $92.5 million, and the company reaffirmed its full-year 2026 revenue guidance of $390 million to $410 million. Shareholders see faster sales growth alongside a larger loss.

Key points

  • Revenue of $98.3 million, up 18% from $83.3 million in the third quarter of 2025; U.S. procedures exceeded 13,400, up about 22%
  • Net loss of $26.5 million, or $0.46 per share, versus a net loss of $21.4 million, or $0.38 per share, a year earlier
  • Adjusted EBITDA loss of $9.8 million versus $7.4 million; operating expenses rose to $92.5 million from $77.2 million
  • Full-year 2026 revenue guidance of $390 million to $410 million reiterated; cash and restricted cash totaled $221.4 million as of September 30, 2026

The filing

CompanyPROCEPT BioRobotics Corp (PRCT)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:18 PM ET
Accession number0001588978-26-000036

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.